Your browser doesn't support javascript.
loading
Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States.
Toumi, Mondher; Wallace, Jack; Cohen, Chari; Marshall, Chris; Kitchen, Helen; Macey, Jake; Pegram, Hannah; Slagle, Ashley F; Gish, Robert G; Ning, Qin; Yatsuhashi, Hiroshi; Cornberg, Markus; Brunetto, Maurizia; van Bömmel, Florian; Xie, Qing; Lee, Dee; Habuka, Noriyuki; Sbarigia, Urbano; Beumont-Mauviel, Maria; Keever, Angelina Villasis; Takahashi, Yasushi; Lu, Yiwei; Liu, Ao; Chen, Qiaoqiao; Ito, Tetsuro; Radunz, Olaf; Puggina, Anna; Hilgard, Gudrun; Chan, Eric K H; Wang, Su.
Afiliação
  • Toumi M; Aix-Marseille University, Jardin du Pharo, 58 bd Charles Livon, Marseille, 13284 Cedex 07, France. Mondher.Toumi@emaud.eu.
  • Wallace J; Department of Public Health, Aix-Marseille University, 27 Boulevard Jean Moulin, Marseille, 13385, France. Mondher.Toumi@emaud.eu.
  • Cohen C; Burnet Institute, 85 Commercial Rd, Melbourne, VIC, 3004, Australia.
  • Marshall C; Hepatitis B Foundation, 3805 Old Easton Rd, Doylestown, PA, 18902, USA.
  • Kitchen H; Clarivate (formerly DRG Abacus), 70 St Mary Axe, London, EC3A 8BE, UK.
  • Macey J; Clarivate (formerly DRG Abacus), 70 St Mary Axe, London, EC3A 8BE, UK.
  • Pegram H; Clarivate (formerly DRG Abacus), 70 St Mary Axe, London, EC3A 8BE, UK.
  • Slagle AF; Clarivate (formerly DRG Abacus), 70 St Mary Axe, London, EC3A 8BE, UK.
  • Gish RG; Aspen Consulting, LLC, 625 S Lincoln Ave #101, Steamboat Springs, CO, 80487, USA.
  • Ning Q; Hepatitis B Foundation, 3805 Old Easton Rd, Doylestown, PA, 18902, USA.
  • Yatsuhashi H; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie Fang Avenue, Hankou, Wuhan, 430030, China.
  • Cornberg M; National Hospital Organization (NHO) Nagasaki Medical Center, 2-1001-1, Kubara, Omura, Nagasaki, 856-8562, Japan.
  • Brunetto M; Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, 852-8520, Japan.
  • van Bömmel F; Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
  • Xie Q; University Hospital of Pisa, Lungarno Pacinotti 43, Pisa, 56126, Italy.
  • Lee D; Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Liebigstrasse 20, 04103, Leipzig, Germany.
  • Habuka N; Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, 227 South Chongqing Road, Shanghai, 20025, China.
  • Sbarigia U; Inno Community Development Organisation, Room 208, Dengzheng Business Center, #57, Dengzhengnan Rd, Yuexiu District, Guangzhou, Guangdong, China.
  • Beumont-Mauviel M; Janssen Pharmaceutical K.K, 3-5-2 Nishi-kanda, Chiyoda-ku, Tokyo, 101-0065, Japan.
  • Keever AV; Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse, B-2340, Belgium.
  • Takahashi Y; Janssen Research & Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA.
  • Lu Y; Janssen Research & Development, 1400 McKeon Road, Spring House, PA, 19002, USA.
  • Liu A; Janssen Pharmaceutical K.K, 3-5-2 Nishi-kanda, Chiyoda-ku, Tokyo, 101-0065, Japan.
  • Chen Q; Janssen China, 14F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, 100025, China.
  • Ito T; Janssen China, 14F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, 100025, China.
  • Radunz O; Janssen China, 14F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, 100025, China.
  • Puggina A; Janssen Health Economics & Market Access (EMEA), 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK.
  • Hilgard G; Janssen Germany, Johnson-u.-Johnson-Platz 1, 41470, Neuss, Nordrhein-Westfalen, Germany.
  • Chan EKH; Janssen Italy, Via Michelangelo Buonarroti, 23, Cologno Monzese, 20093, Italy.
  • Wang S; Janssen Germany, Johnson-u.-Johnson-Platz 1, 41470, Neuss, Nordrhein-Westfalen, Germany.
BMC Public Health ; 24(1): 611, 2024 Feb 26.
Article em En | MEDLINE | ID: mdl-38408941
ABSTRACT

BACKGROUND:

People with chronic hepatitis B (CHB) commonly experience social and self-stigma. This study sought to understand the impacts of CHB-related stigma and a functional cure on stigma.

METHODS:

Adults with CHB with a wide range of age and education were recruited from 5 countries and participated in 90-minute qualitative, semi-structured interviews to explore concepts related to CHB-associated stigma and its impact. Participants answered open-ended concept-elicitation questions regarding their experience of social and self-stigma, and the potential impact of reduced CHB-related stigma.

RESULTS:

Sixty-three participants aged 25 to 71 years (15 from the United States and 12 each from China, Germany, Italy, and Japan) reported emotional, lifestyle, and social impacts of living with CHB, including prejudice, marginalization, and negative relationship and work experiences. Self-stigma led to low self-esteem, concealment of CHB status, and social withdrawal. Most participants stated a functional cure for hepatitis B would reduce self-stigma.

CONCLUSIONS:

CHB-related social and self-stigma are widely prevalent and affect many aspects of life. A functional cure for hepatitis B may reduce social and self-stigma and substantially improve the health-related quality of life of people with CHB. Incorporating stigma into guidelines along with infectivity considerations may broaden the patient groups who should receive treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite B Crônica / Hepatite B Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite B Crônica / Hepatite B Idioma: En Ano de publicação: 2024 Tipo de documento: Article